Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Toripalimab and Endostar for Stage II Melanoma
NCT06965231Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jan 2025
- Primary completion
- Dec 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab, endostar in Malignant Melanoma (MM), sponsored by Fudan University. Started Jan 2025; status: recruiting.
02
Drugs
toripalimabendostar
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT06965231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06965231.